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Abstract: Coagulase-negative staphylococci (CoNS) have emerged as major pathogens in 
healthcare-associated facilities, being S. epidermidis, S. haemolyticus and, more recently, S. lugdunen-
sis, the most clinically relevant species. Despite being less virulent than the well-studied pathogen 
S. aureus, the number of CoNS strains sequenced is constantly increasing and, with that, the number 
of virulence factors identified in those strains. In this regard, biofilm formation is considered the 
most important. Besides virulence factors, the presence of several antibiotic-resistance genes identi-
fied in CoNS is worrisome and makes treatment very challenging. In this review, we analyzed the 
different aspects involved in CoNS virulence and their impact on health and food. 
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1. Introduction 
Staphylococci are a widespread group of bacteria that belong to human and animals 
normal microflora [1]. Staphylococcus genus comprises two main groups, the coagulase-
negative staphylococci (CoNS) and coagulase-positive staphylococci (CoPS), which were 
defined according to their ability to produce the enzyme coagulase [2]. Staphylococcus spe-
cies were first characterized by Friedrich Rosenbach, who established that yellow/orange 
colonies corresponded to CoPS species and white colonies to CoNS [3]. Among Staphylo-
cocci, Staphylococcus aureus, belonging to the CoPS group, and Staphylococcus epidermidis, 
from the CoNS group, are the most frequently isolated of each group, the reason why 
most of the CoNS studies are focused on these species [4]. Nonetheless, CoNS cover a 
large and continuously expanding group of bacteria, with more than 50 species described 
so far, which are currently distributed into 41 main species, divided into more than 20 
subspecies (reviewed in [5]). Since CoNS are common colonizers of human skin, they have 
been recurrently considered culture contaminants rather than recognized as the causative 
agent of important infections [6,7]. Despite their benign interaction with the host, it is now 
known that these species can cause critical infections, especially in immunocompromised 
patients, the reason why they are currently acknowledged as opportunistic pathogens and 
have been gaining increasing importance in the healthcare field (reviewed in [8,9]). 
The increase of CoNS impact on the clinical field was emphasized by the extensive 
medical progress, where the use of implantable medical devices and the increasing num-
ber of vulnerable patients have allowed CoNS to cause significant infections in humans 
[10]. More importantly, these factors have elevated the number of morbid, chronically ill 
and immunocompromised patients, as well as the mortality rates related to CoNS [11,12]. 
Moreover, as CoNS are known to colonize both farm and domestic animals, they may as 
well establish infections upon opportunity, although to a lesser extent. For instance, sev-
eral bovine mastitis infections associated with CoNS have increasingly being reported 
over the years [13–15]. Additionally, several studies demonstrated that infections caused 
Citation: França, A.; Gaio, V.; Lopes, 
N.; Melo, L.D.R. Virulence Factors in 
Coagulase-Negative Staphylococci. 
Pathogens 2021, 10, 170. 
https://doi.org/10.3390/ 
pathogens10020170 
Academic Editor: Wioleta  
Chajȩcka-Wierzchowska 
Received: 30 December 2020 
Accepted: 29 January 2021 
Published: 4 February 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and insti-
tutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (http://cre-
ativecommons.org/licenses/by/4.0/). 
Pathogens 2021, 10, 170 2 of 46 
 
 
by these species affect debilitated domestic animals as cats with conjunctivitis, upper res-
piratory tract and skin or wound infections [16], or dogs with keratitis or urinary tract 
infections [17,18]. This is especially concerning, since it was already demonstrated that 
CoNS may be transferred from pets to their owners [19,20]. Moreover, some farm animals 
such as chickens are known to be the main reservoirs of antimicrobial resistance genes 
[21]. Importantly, CoNS have also been detected as contaminants of food products. Con-
tamination with CoNS has been found in ready-to-eat foods of animal origin [22,23], re-
tailing raw chicken meat [24], and in bulk tank milk or minced meat [25]. Altogether, the 
infections caused by CoNS species have become more frequent and harmful to both hu-
mans and animals, and, subsequently, entail an increase in the economic burden [26]. 
The virulence factors of CoNS have been considered to a lesser extent than CoPS (e.g., 
S. aureus) since they are coagulase “free”. Nevertheless, the continuous findings and up-
dates on species and subspecies have revealed a heterogeneous group, ranging from non-
pathogenic to facultative pathogenic species, with distinct virulence potential levels [27]. 
Some isolates have become increasingly concerning, as Staphylococcus lugdunensis, which 
lately has been recognized as a pathogenic bacterium with a high virulence impact [28]. 
S. lugdunensis can cause highly acute and destructive events of infective endocarditis (IE), 
leading to higher mortality rates than other CoNS species, which generally cause less se-
vere infections [29]. Despite some similarities with S. aureus, CoNS are generally less path-
ogenic and present a smaller array of virulence factors, being less studied than the major 
CoPS pathogen (reviewed in [8]). Nevertheless, these species deserve special attention due 
to their significant impact on the clinical and food fields, resulting from several virulence 
factors. Colonization of surfaces and formation of biofilms by CoNS bacteria has long been 
considered their main virulence factor, being known that the heterogeneity of bacteria 
within biofilms may contribute to their persistence with emphasis on persister cells, viable 
but non-culturable (VBNC) cells and small colony variants (SCVs). Moreover, resistance 
to antibiotics and the production of bacteriocins and enterotoxins are aspects also contrib-
uting to their virulence. 
In order to enhance the knowledge on CoNS pathogenicity, these virulence factors 
and their impact on health and food will be further discussed in this review. 
2. Adhesion and Biofilm Formation 
In the natural, industrial, and clinical environments, bacteria grow predominantly in 
biofilms. Biofilms are multicellular and structured communities of microorganisms ad-
hered to a substratum and embedded in a matrix of extracellular polymeric substances 
[30]. These communities provide protection from several external stresses such as antimi-
crobial agents [31] and the attacks mounted by the host defenses [32,33] facilitating, thus, 
the survival of the cells inside the biofilm. As referred to above, CoNS capacity to form 
biofilms is considered a major virulence factor and, thus, the mechanisms underlying bio-
film formation gained special attention in the last decades. Biofilm formation by CoNS is 
an intricate and multistep process that can be primarily divided into three phases: (i) ad-
hesion or attachment to a surface, (ii) maturation into a complex multicellular structure 
and (iii) dispersion of cells into the surrounding environment [34] (Figure 1). 




Figure 1. CoNS virulence factors summary illustration. CoNS species are equipped with several strategies to overcome 
less favorable conditions and, thus, to survive in a variety of different environments. Amongst all strategies, the capacity 
to form biofilms is one of the most important. Biofilm formation starts with the adhesion of free-floating cells to a surface, 
either abiotic or biotic, and proceeds through the division and aggregation of cells, which creates the characteristic multi-
layered structure. In addition, an extra-polymeric protective matrix is produced by the cells. This is defined as the matu-
ration phase. This phase is mediated by adhesins, but also by molecules with disruptive properties, such as PSMs, since 
these are necessary to form channels that ensure the flow of nutrients to all biofilm layers. Moreover, as could be expected, 
PSMs have a pivotal role in the final step of the biofilm lifecycle, the dispersion, as it allows biofilm cells to escape and 
colonize other places. It is important to stress that, in the illustration, only a brief description of some of the molecules 
involved in the several mechanisms employed by CoNS to respond and subsist to external stresses are depicted. Aap, 
accumulation associated protein; AMPs, Antimicrobial peptides; chrDNA, chromosomal DNA; eDNA, extracellular DNA; 
MSCRAMMs, Microbial surface components recognizing adhesion matrix molecules; PBP2/a, penicillin-binding protein 2 
and 2a; PNAG, poly-N-acetylglucosamine; PSMs, phenol-soluble modulins; Sbp, Small basic protein; TAs, teichoic acids; 
VBNC, Viable but-non culturable cells. 
Surface-associated adhesins have an important role in biofilm formation, both in the 
initial adhesion to host proteins and tissues, and biofilm maturation. These adhesins com-
prise covalently and non-covalently anchored proteins, as well as non-proteinaceous fac-
tors (reviewed in [35–38]). Covalently anchored proteins, or also called cell wall-anchored 
(CWA) proteins, are characterized by the presence of the LPXTG motif, which is recog-
nized by the sortase enzyme that, in turn, conducts the process of anchoring the protein 
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to the peptidoglycan [39]. Briefly, in S. epidermidis, CWA proteins can be divided, based 
on the presence of common characteristic domains, into two main families [36]: (i) micro-
bial surface component recognizing adhesive matrix molecules (MSCRAMM), which in-
tegrate members of the serine-aspartate repeat (Sdr) and S. epidermidis surface (Ses) pro-
teins and (ii) G5-E repeat proteins family that includes the accumulation associated pro-
tein (Aap). A defining feature of the MSCRAMMs family is the presence of two tandemly 
linked IgG-like folded domains, which can engage in ligand binding by the “dock, lock 
and latch” mechanism [40]. This mechanism enables a stable adhesin-ligand complex 
which is important to ensure a tight binding under the fluid shear forces that frequently 
occurs around indwelling medical devices (IMD) [40]. Moreover, there are also uncatego-
rized CWA proteins putatively involved in biofilm formation as, for instance, biofilm-
homolog protein (Bhp) [36]. Within the group of the non-covalently anchored cell wall are 
the autolysins/adhesins AtlE and Aae. Lastly, the non-proteinaceous group is composed 
of teichoic acids (TAs) and the polysaccharide intercellular adhesion (PIA) [35–38]. The 
function of these molecules will be briefly discussed in this section in the context of their 
contribution to biofilm formation. 
2.1. Initial Adhesion 
CoNS have the capacity to adhere to several different surfaces including abiotic (pol-
yethylene, stain steel, rubber, and glass) or biotic surfaces (living tissue or abiotic surfaces 
covered with proteins), the former being more relevant in the context of food processing 
industry [41] and the last more relevant in clinical settings [42]. 
2.1.1. Initial Adhesion to Abiotic Surfaces 
The adhesion to abiotic surfaces is primarily mediated by non-specific physicochem-
ical forces such as hydrophobic and electrostatic interactions [43,44]. Nevertheless, spe-
cific bacterial surface molecules can also foster this process. 
AtlE, a major autolysin of S. epidermidis, is primarily involved in cell wall turnover 
and cell division and lysis [45]. However, it was shown that AtlE-mediated cell lysis re-
sulted in DNA release (extracellular DNA, eDNA), which, in turn, promoted the adhesion 
of the surrounding cells to the polystyrene surface [46]. Thus, AltE seems to mediate ad-
hesion through the release of DNA rather than acting itself as an adhesin. Another mech-
anism for the generation of biofilm eDNA in S. lugdunensis involves the competence pro-
tein ComEB, presumably via active DNA secretion [47]. Homologous autolysins were re-
ported in other CoNS species, such as S. caprae (AtlC) [48], S. warneri (Atl [49]), S. sapro-
phyticus (Aas) [50], and in S. lugdunensis (AtlL) [51]. Aae, another autolysin/adhesin found 
in S. epidermidis, is as well implicated in the initial adhesion to abiotic surfaces [42,52]. The 
protein Aap also participates in the initial adhesion to abiotic surfaces [53,54]. This protein 
consists of an N-terminal Domain-A and a C-terminal Domain B, the Domain-A being the 
one involved in the adhesion to abiotic surfaces [53]. Other studies have suggested the 
involvement of ClpP [55], SdrF [56], and Bhp [57] in this process. 
In respect to non-proteinaceous molecules, TAs play an important role in initial ad-
hesion. TAs are anionic glycopolymers highly abundant in the cell wall that are involved 
in several essential cell functions (reviewed in [58,59]). TAs are divided into wall teichoic 
acids, which are covalently attached to the peptidoglycan layer, and lipoteichoic acids that 
are anchored to the plasma membrane. Both molecules are tailored with D-alanine esters 
by a process called D-alanylation [60]. This process balances the charge of both molecules. 
It was shown, in S. aureus, that mutants lacking the genes encoding the enzymes necessary 
to incorporate D-alanine into TAs resulted in a stronger negative net charge on the bacte-
rial cell surface [61], thereby attenuating initial attachment to plastic surfaces [62,63]. Alt-
hough TAs are less studied in CoNS, in S. epidermidis, the lack of wall teichoic acids re-
sulted in impaired initial adhesion to polystyrene surfaces [64]. 
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2.1.2. Initial Adhesion to Abiotic Surfaces 
When it comes to biotic surfaces such as living tissues or medical devices that are 
readily coated by host proteins after implantation, bacterial adhesion is facilitated by a 
different set of interactions, mostly by ligand–receptor specific interactions between host 
cells or extracellular matrix proteins and bacterial surface-associated adhesins. S. epider-
midis and S. aureus express dozens of MSCRAMMs that bind to human matrix proteins 
such as fibrinogen, fibronectin, vitronectin and collagen, and often combine a binding ca-
pacity for several different matrix proteins [65,66]. As such, MSCRAMMs present a key 
function in initial adhesion to biotic surfaces, the role of SdrG being the best well-known. 
SdrG, also named Fbe, binds to its ligand, fibrinogen, by the “dock, lock, latch” mecha-
nism. Studies performed to evaluate S. epidermidis SdrG function in the context of bacterial 
adhesion showed that this adhesin is important in vitro, not only to mediate bacterial 
binding to fibrinogen coated-surfaces [40] but for platelet adhesion and aggregation [67]. 
More recently, it has been suggested that SdrG can bind to host cells, such as osteoblasts 
[68]. SdrG has also shown to be important in vivo for the colonization of implanted mate-
rial [69]. A homolog to SdrG, the fibrinogen binding protein (Fbl), was found in S. lug-
dunensis [70] and is likely to be involved in this bacterium initial adhesion to biotic sur-
faces. 
Also involved in the adhesion of S. epidermidis to biotic surfaces are the proteins SdrF 
[71,72], SesC [73] and Embp [74], due to their affinity to, respectively, collagen and keratin, 
fibrinogen and fibronectin. In other CoNS additional adhesins with specificity to bind col-
lagen were found, such as the SrdX in S. capitis [75], and the protein SrdI in S. saprophyticus 
that binds to both collagen [76] and fibronectin [77]. 
Besides the aforementioned role of the autolysins and TAs in the initial adhesion to 
abiotic surfaces, these molecules also present an important role in bacterial cells adhesion 
to biotic surfaces. The bifunctional autolysins AtlE and Aae, due to their affinity to vitron-
ectin (AtlE and Aae), fibrinogen (Aae) and fibronectin (Aae) [46,52] and TAs because of 
their capacity to bind fibronectin [63,64] and adhere to epithelial and endothelial cells 
[78,79]. 
2.2. Maturation 
After adhering to the surface, bacterial cells start dividing, forming aggregates and 
shaping its distinctive 3D appearance. To maintain a robust structure, cells need not only 
to be attached to a surface but also to stick to each other. As such, biofilm cells are embed-
ded in a matrix composed of self-produced polysaccharides, proteins, lipids, eDNA and 
RNA, and TAs [80,81], but can also include molecules of the surrounding environment 
[82,83]. This extracellular matrix is fundamental for structural and functional roles as it 
provides stability against mechanical forces and creates a unique environment that is es-
sential for the biofilm lifestyle [82,84]. Importantly, the matrix also plays a part in protec-
tion against disinfectants, antibiotics, immune cells activity, and bacteriophage (phage) 
predation [36,85,86]. Nevertheless, to ensure a functional organization, where nutrients 
are distributed into the deeper layers of the biofilm, channels need to be molded. To do 
so, disruptive forces need to be applied. Thus, during the biofilm maturation process, 
there is a thin balance between adhesive and disruptive forces [34]. 
2.2.1. Intercellular Aggregation Accomplished by Adhesive Forces 
In S. epidermidis, the most predominant adhesive molecule is the PIA, also named 
poly-N-acetyl glucosamine (PNAG) due to its chemical composition [87]. PNAG is syn-
thesized by the enzymes codified by the intercellular adhesion (ica) locus, which is com-
posed of the genes icaA, icaD, icaB, icaC [88], and the regulatory gene icaR, which is located 
upstream of the icaADBC and, thus, divergently transcribed [89]. In S. lugdunensis, even 
though icaADBC homologs were identified, the locus organization differs substantially 
from that of other staphylococci [90]. In addition, the icaR gene is absent even though 
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another ORF was found in this position [90]. These differences may suggest an evolution-
ary adaptation that is likely to confer an advantage to this species [90,91]. 
Due to its proven fundamental role for biofilm structure, PNAG was for many years 
thought to be a requisite for biofilm formation. However, strains that did not harbor the 
ica genes were still able to form a biofilm, although less robust [92,93]. Thus, it was hy-
pothesized that molecules other than PIA were implicated in biofilm maturation. We thus 
learned that biofilm formation can be supported or completely mediated by proteins [34–
36]. In fact, S. lugdunensis biofilms are mostly composed of proteins rather than PNAG 
[90,93]. It was found that IsdC, an iron-binding protein, has a pivotal role in S. lugdunensis 
biofilm accumulation by promoting cells aggregation through homophilic interactions be-
tween IsdC molecules on neighboring cells [94]. 
Regarding proteins involvement in biofilm maturation, Aap is one of the best well-
studied proteins in S. epidermidis. Biofilm accumulation by Aap is determined by Domain-
B that becomes active only upon cleavage of the native protein [95,96]. Accordingly, the 
matrix of S. epidermidis biofilms is composed of a mixture of fully and partially cleaved 
proteins [35]. Recently, it was shown that the bacterial metalloprotease SepA is able to 
cleave the Domain-A of Aap resulting in enhanced biofilm accumulation in S. epidermidis 
[97]. Nevertheless, other unknown proteases, from either bacteria or the host, can cleave 
Aap, thereby contributing to biofilm accumulation. Aap promotes cell–cell adhesion by 
forming twisted rope-like structures through a Zn2+ dependent mechanism [98,99]. In ad-
dition, Aap is known to interact with N-acetyl glucosamine moieties potentially binding 
to PNAG, forming a protein-polysaccharide biofilm network [100]. Similarly, Embp seems 
to interact with PNAG contributing, this way, to the biofilm maturation, as, alone, it seems 
to be insufficient to create biofilm aggregation [74]. 
More recently, Sbp was also found to play an important role in S. epidermidis biofilm 
accumulation, having particular importance in the development of the biofilm architec-
ture [101]. Sbp forms amyloid-like fibrils that function as a biofilm scaffold instead of di-
rectly inducing cell aggregation [102]. In addition, it was reported that Sbp interacts, 
through the fibrils formed, with the Domain-B of Aap also contributing to biofilm accu-
mulation [102]. 
Other proteins such as SesC [73,103,104], SesJ [105], and SesI [106] were suggested to 
be involved in biofilm maturation. However, more studies are needed to undercover their 
relevance and mechanisms of action. Still, within the proteins domain, it is important to 
note that MSCRAMMs can also promote biofilm accumulation through homophilic inter-
actions between MSCRAMMs in neighboring cells [107]. 
Lastly, as a result of their anionic character, both TAs [62,108] and eDNA originated 
from AtlE-mediated autolysis [109–111], can have accessory functions in aggregation by 
interacting with other surface polymers, via electrostatic interactions, thereby acting as a 
“glue”. 
2.2.2. Biofilm Structuring Accomplished by Disruptive Forces 
As aforementioned, the disruption of the intercellular interactions is necessary for 
the formation of channels that ensure the passage of nutrients and waste in and out of the 
biofilm. In staphylococci, proteases [112], nucleases [113], and phenol-soluble modulins 
(PSMs) [114,115] have been implicated in this role. However, only PSMs have been con-
sistently demonstrated to assist in biofilm structuring, both in vitro and in vivo (reviewed 
in [116]). 
PSMs are amphipathic α-helical molecules with strong surfactant-like properties. As 
such, it is thought that PSMs contribute to biofilm structuring by disrupting non-covalent 
interactions that occur between biofilm matrix molecules [42]. S. epidermidis produces six 
PSM peptides: PSMα, PSMβ1, PSMβ2, PSMδ, PSMε, and PSMγ (δ-toxin) [117], which are 
encoded in the chromosome, and the PSM-mec that is encoded in the mobile genetic ele-
ment SCCmec [118]. PSMβ peptides have been shown to be a key effector in biofilm struc-
turing and dispersion both in vitro and in vivo [114]. A deletion mutant of the β-type PSMs 
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developed a more compact and extended biofilm than the parental strain [114]. As could be 
expected, PSMβ also has a role in the biofilm dispersion phase, the last step of the biofilm 
lifecycle. It was shown that, depending on the level of production, PSMβ can lead to either 
biofilm structuring (medium concentrations) or biofilm dispersion (higher concentrations) 
[114]. The production of PSMs is strictly regulated by the accessory gene regulator (agr) 
quorum-sensing (QS) system, which will be discussed further in Section 2.4 
2.3. Dispersion 
As the biofilm grows older, cell clusters may leave the biofilm [119]. This is an im-
portant phase as it contributes to biofilm expansion, bacteria survival, and disease trans-
mission [119]. While not as explored as the initial adhesion or biofilm maturation, the dis-
persion step is a complex process having drawn some attention in past years, in particular, 
in oral bacteria and Pseudomonas aeruginosa, with only a few studies performed in staphy-
lococcal species. 
Currently, the dispersion phase is divided into two mechanisms, which are defined 
based on the initial trigger: (i) passive dispersion, also called detachment, which includes 
processes mediated by external factors, and (ii) active dispersion, which integrates pro-
cesses actively employed by bacteria in response to external signals [120]. Passive disper-
sion can occur by several different mechanisms such as abrasion (removal of cells due to 
collision with particles), grazing (due to the activity of eukaryotic predators), erosion, and 
sloughing (removal of cells or larger pieces of the biofilm by fluid shear) (reviewed in 
[119–121]). Also in this category are the techniques developed to induce detachment such 
as enzymes with the capacity to degrade biofilm matrix macromolecules (mainly polysac-
charides and proteins) and physical biofilm disruption [119]. One of the best well-known 
enzymes with the capacity to disperse S. epidermidis biofilms is Dispersin B [122], a PNAG-
degrading enzyme produced by Actinobacillus actinomycetemcomitans [123]. To what con-
cerns the active mechanisms of dispersion and the effector molecules associated, as de-
tailed in Section 2.2.2, PSMs, in particular, β-type PSMs, are the major players. 
Even though a lot of research has been focused on the characterization of biofilm cells 
phenotype, very little is known about the cells released from the biofilm. Initially, it was 
hypothesized that, after leaving the biofilm, cells would immediately revert to their plank-
tonic phenotype [112]. However, later on, other studies have demonstrated that cells re-
leased from biofilms present a particular phenotype, although transient, that is different 
from both planktonic and biofilm cells [124,125]. In S. epidermidis, the cells released from 
biofilms present a higher tolerance than biofilm or planktonic cells to some antibiotics 
[126] and elicit a more pro-inflammatory response in a murine model of hematogenous 
disseminated infection [127]. Nevertheless, more studies are necessary to further under-
stand the mechanisms behind biofilm dispersion and the role of the cells released in the 
virulence of CoNS. 
2.4. Regulation of Biofilm Formation 
To form the complex structure displayed in biofilms, bacteria have to tightly coordi-
nate every single step of the process. As such, there are several regulatory systems in-
volved in biofilm formation by staphylococcal species, the agr QS system being one of the 
best characterized (reviewed in [37,128,129]). 
Shortly, the agr system is a classical two-component signaling system that is activated 
by an autoinducing peptide (AIP) when this reaches a critical concentration, i.e., 
“quorum” cells in the population. This signal is sensed by bacteria that synchronize their 
response. The agr locus codifies the RNAII and RNAIII transcriptional units that are reg-
ulated by two different promoters, respectively, P2 and P3. The RNAII transcript encodes 
the genes agrBDCA and the RNAIII the hld gene that is responsible for the production of 
the PSMγ (δ-toxin) [130]. Interestingly, although S. lugdunensis holds an agr-like system, 
the hld gene is encoded elsewhere [131,132]. Mechanistically, the signaling cascade starts 
with agrD, which is post-translationally modified and exported by AgrB. The extracellular 
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accumulation of the AIP is detected by the histidine kinase AgrC that, in turn, activates 
the DNA-binding regulator AgrA. This activates P2 and P3 promoters [130,133], as well 
as the ones controlling the expression of α- and β-type PSMs transcripts [134]. Lastly, 
RNAIII, the effector of the agr system, directly controls the upregulation of genes encoding 
enzymes, toxins, and PSMs, and it downregulates several genes encoding surface-associ-
ated adhesins [135]. This regulation occurs either by modulating transcription initiation 
or at the post-translational level by interacting with the target gene transcript [133]. 
Probably related to agr system downregulation of adhesins and upregulation of PSM 
and other proteases, the dysfunctionality of the agr system in S. epidermidis results in 
thicker biofilms with defects in dispersion capacity [32,136]. Although one may think that 
the agr negative phenotype is not advantageous as it impairs the bacterium capacity to 
disseminate, this phenotype is frequently seen in bacteria isolated from catheter-related 
infections. This suggests that mutations in the agr system have an adaptive advantage to 
cause IMD-associated infections [32], possibly because a thicker biofilm is likely to confer 
fitness advantage in chronic infections [32,137,138]. It was proposed that the naturally oc-
curring mutations in the agr system are likely to be related to the high metabolic burden 
that the maintenance of the agr system poses to the cell [129]. 
A second QS system molecule influencing biofilm formation in CoNS is the autoin-
ducer-2 (AI-2) that belongs to the LuxS/AI-2 QS system. Due to its wide distribution in 
many bacterial species, this seems to be an interspecies communication system [129]. AI-
2 controls biofilm formation by positively regulating the ica operon repressor icaR. In S. 
epidermidis, the absence of AI-2 resulted in higher expression of PNAG and, consequently, 
increased biofilm formation [139]. In addition, the absence of AI-2 led to increased viru-
lence in central venous catheter-associated infection model [139]. It is important to men-
tion that studies performed with other S. epidermidis strains reported a contradictory ef-
fect, where AI-2 leads to icaR negative regulation [140]. 
Biofilm formation can also be regulated by different factors such as Sigma B (SigB) 
and the staphylococcal accessory regulator A (SarA). Sig B is an alternative sigma factor 
of RNA polymerase, which leads to global changes in gene expression when activated by 
stressful situations. The lack of SigB in S. epidermidis resulted in increased expression of 
icaR, which repressed the production of PNAG and, consequently, impaired biofilm for-
mation [141,142]. In addition, the disruption of SigB production led, in S. epidermidis, to 
impaired colonization in a catheter-associated infection model [143]. Lastly, SarA is a gen-
eral transcription factor that binds to AT-rich sequences, activating or repressing the ex-
pression of the target genes [129]. Nevertheless, the effect of SarA in S. epidermidis biofilm 
formation is highly strain-dependent. While in some strains SarA mutation led to a bio-
film-negative phenotype through the downregulation of ica operon expression by an IcaR-
independent pathway [144], in aap- and ica-negative strains resulted in higher biofilm for-
mation capacity through the overexpression of the protein Empb and release of eDNA by 
a SepA and AtlE-mediated process [145]. 
Additionally, although not a true regulator, the insertion of the insertion sequence 
(IS)256 in ica genes abolishes PNAG production [146]. 
3. Persistence as a Tolerance Mechanism 
Bacteria can quickly respond to unfavorable environmental or stressful conditions by 
lowering their metabolic activity, altering their gene expression, or by inducing genetic 
changes, entering a state of dormancy [147]. Biofilms per se are an example of a bacterial 
stress condition, namely due to nutrients and oxygen deprivation [148]. Biofilm-embed-
ded communities are characterized by the presence of heterogeneous cells, with distinct 
physiological states, whose emergence depends on the micro-environmental conditions 
in its surroundings [149,150]. Therefore, since the access to nutrients and oxygen at the 
deeper biofilm layers is more unfavorable than in the upper layers, variant subpopula-
tions of cells can emerge [151]. Importantly, CoNS can switch to a different mode of 
growth and adjust their gene expression patterns, metabolic activity, and phenotype, to 
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promote their survival in stressed or limited environmental conditions [152–154]. Re-
cently, two CoNS species, namely S. epidermidis and S. haemolyticus, exhibited different 
strategies to overcome the impact of nutrient depletion [155]. While S. epidermidis man-
aged to survive through the accumulation of cardiolipin and/or lyso-cardiolipin, S. haemo-
lyticus employed a completely different strategy, surviving the nutrient depletion created 
by building an extremely simple lipidome, made of only diglucosyl-diacylglycerol and 
phosphatidylglycerol. Additionally, the authors claimed that bacteria at the stationary 
phase seemed to have similar behavior as when exposed to starvation [155]. Considering 
the entrance of bacteria into dormancy upon stressful conditions (e.g., starvation), the 
analysis of bacteria in the stationary phase may highlight some potential strategies used 
to survive those environments. Some dormancy phenotypes have been already found and 
will be detailed below. 
Bacterial Cells Dormant Phenotypes: A Tolerance Mechanism 
Several authors have been debating the possible different phenotypic states that bac-
teria can undertake, which enable a diminished inflammatory response and higher toler-
ance to the antimicrobial therapies applied [156–158]. Persisters, VBNC, and SCVs are the 
physiological states currently under debate. 
In the 1940s, persister cells were described and defined as a group of cells that exhibit 
a drug-tolerant phenotype [159,160]. This small subpopulation of cells, when exposed to 
antibiotic pressure, becomes slow-growing by reducing their metabolism, rather than pro-
moting an active response. Once the stress is removed, persister cells can resume growth, 
contributing to the antibiotic tolerance observed among biofilms cells [161,162]. The for-
mation of persister cells in culture can be reached through two distinct ways: triggered or 
spontaneously. Triggered persisters, also defined as type I persisters, emerge when cells 
encounter some stress, such as starvation, and the persistence level may depend on the 
type and the intensity of the trigger [161]. Spontaneous persisters (type II persisters) occur 
during the stationary phase culture and persist as long as the steady-state growth is main-
tained [161,163,164]. The presence of persisters can be found on both planktonic and bio-
film populations, as observed in S. epidermidis cells when exposed to levofloxacin and van-
comycin [165]. Goneau et al. were able to induce the formation of persister cells in S. sap-
rophyticus using antibiotics from different classes (ciprofloxacin, ampicillin, and gentami-
cin), exhibiting a greater antibiotic tolerance during the stationary phase than in the expo-
nential phase [166]. A recent study on CoNS demonstrated the formation of persister cells 
after exposure to various biocides (polymyxin, sodium sulfacetamide, lysing solution). 
Independently of the biocide tested, S. epidermidis and S. capitis strains were able to form 
persister cells [167]. 
Later in 1982, the existence of another phenotype, viable but non-culturable cells, was 
proposed. These cells were identified by Xu et al., which showed that these bacterial cells 
could not grow on routine or selective media [168]. Moreover, VBNC cells were discrimi-
nated from dead cells, since they were similar to live cells, containing an intact membrane, 
an active mRNA transcription, metabolic activity, and respiration [169,170]. At least 
eighty-five bacterial species have been shown to enter a VBNC state, including foodborne 
and clinical pathogens [171]. To date, S. epidermidis is the only known CoNS reported to 
adopt this survival strategy [172]. Cerca and co-workers have developed a model where 
the proportions of VBNC cells in S. epidermidis biofilms can be modulated. Briefly, the 
authors demonstrated that the induction of VBNC cells could be achieved by increasing 
the glucose concentration in the growth medium and that this induction could be some-
how prevented by the supplementation of the medium with Ca2+ and Mg2+ [172]. Several 
methods have been suggested to uncover the existence of VBNC cells. Assessing viability 
and culturability is the key to provide an estimation of the number of these cells [173]. 
Therefore, numerous approaches have been combined to evaluate cell viability and cul-
turability, such as the usage of fluorescent microscopy or flow cytometry and colony form-
ing units (culture methods), respectively [174,175]. Additionally, a study demonstrated 
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that the combination of LIVE/DEAD staining with quantitative PCR can also reveal the 
presence of VBNC cells in CoNS biofilms [175]. Over the years, the similarities and/or 
differences between persisters and VBNC cells phenotypes have been a motive for intense 
debate since both are employed by bacteria under the same stress conditions. Some au-
thors suggest that persister cells are indeed VBNC cells [176,177], while others oppose this 
interpretation as the similarities hypothesized for both phenotypes were described in dif-
ferent species [178]. Moreover, it has been suggested that persister cells are more associ-
ated with antibiotic stress and can easily regain growth after antibiotic removal, whereas 
the VBNC state seems to be linked to different environmental conditions and, in some 
species, the removal of the stress factor is not enough to revert the phenotype, requiring a 
more specific condition to revive the cells [178]. 
SCVs were first described more than 100 years ago [179]. These cells are known as 
natural occurring bacterial subpopulations, demonstrating a similar slow growth rate as 
the previously described dormant phenotypes and, as the name implies, exhibit a smaller 
size than their parental wild-type bacteria, setting a challenge in their identification [180]. 
Since then, SCVs were found in a wide range of bacterial species such as S. aureus [181] 
and CoNS species and are generally correlated to biomaterial-associated infections 
[180,182]. Several aspects of the pathogenic potential of SCVs have been described, mainly 
their enhanced biofilm-forming ability [183], evasion from the immune system response 
[184], and their resistance against antimicrobial agents [185,186]. Interestingly, Onyango 
et al. revealed that S. epidermidis and S. lugdunensis were capable of developing SCVs phe-
notypes following the exposure to a wide range of environmental stress conditions, such 
as pH alterations (pH5), osmotic stress (0–20% NaCl), low temperature (4 °C), and to the 
presence of antimicrobial agents (vancomycin and penicillin G) [187]. Additionally, the 
authors found a thicker extracellular matrix in all SCVs populations in comparison to their 
corresponding control cells [187]. Therefore, this feature may represent an adaptation in 
biofilm formation to provide a stronger defense against antimicrobial agents, as suggested 
by other authors [188]. 
However, the genetic bases underlying these dormant phenotypes are still not well 
characterized. Therefore, it is important to recognize the impact of these dormant pheno-
types, as a tolerance mechanism adopted by CoNS, in nowadays clinical infections and 
food safety. 
4. Antibiotic Resistance 
The significance of CoNS species has increased over the years, mainly due to their 
multidrug resistance profile [24,189–193] and their ability to grow as biofilms, which are 
even more refractory to antibiotics as reported worldwide [31,191,194–197]. Several mech-
anisms have been discussed concerning the increase of antimicrobial resistance, from 
which (i) the barrier formed by the matrix surrounding the cells within biofilms, whose 
thickness and composition can hinder the penetration and/or diffusion of antibiotics [198], 
and (ii) the fact that staphylococci biofilms are very prone to mutations that may increase 
their resistance towards antibiotics [199,200] stand out. Moreover, the presence of cells 
with distinct physiologies, such as persister, SCVs and VBNC cells, also increases toler-
ance to antibiotics [201,202] (reviewed in [203–205]). Another possible explanation for the 
high rate of antimicrobial resistance is that CoNS share the same niches of colonization 
with S. aureus, allowing horizontal gene transfer (HGT) of several genes and mobile ele-
ments encoding for antibiotic resistance [206]. In fact, HGT among staphylococcal species 
has already been proven with the detection of many resistant phenotypes related to mul-
tiresistant genes located on mobile genetic elements [25,207,208]. The importance of mo-
bile genetic elements as virulence factors in CoNS will be further explored in more detail 
in Section 5. 
Fighting these threats has hence become of ultimate importance, with the main strat-
egy being the application of a cocktail of several antibiotics for a prolonged period of time 
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[24,209–213]. However, the high tolerance of CoNS biofilm cells commonly causes the fail-
ure of antibiotics, even when the most severe therapies are used [214] and, in the cases 
associated with the use of IMD, may implicate the removal of the infected device, resulting 
in prolonged hospital stays and increased morbidity and mortality rates [42,203,215]. In-
terestingly, the problematic of IMD-associated infections was emphasized by a recent 
study that assessed S. epidermidis in-host evolution in a case of pacemaker-associated en-
docarditis, which has shown that increased tolerance to antibiotics and capacity to form 
biofilms  occurred during the course of infection [216]. This helps to explain the often in-
efficacy of antibiotics to treat S. epidermidis infections. Besides the impact on human health, 
CoNS infections and contamination are also alarming from the veterinary and food pro-
duction standpoint, where antimicrobial resistance has correspondingly been reported 
(reviewed in [14,24,217,218]). Among CoNS strains, antimicrobial resistant rates have 
been increasing over the years, resulting from (i) the incorrect and/or widespread use of 
antibiotics, (ii) the use of antibiotics in domestic and farm animals, (iii) the low discovery 
rate of newer antibiotics, and (iv) due to the intrinsic environmental conditions contrib-
uting to the adaptation of bacteria to antimicrobial compounds [219–226]. 
4.1. Resistance to β-lactams 
Some of the more representative species of CoNS are known to present a high re-
sistance rate to methicillin [25,227], as, for instance, S. epidermidis [228], S. haemolyticus 
[229], and S. sciuri [230]. This phenotype is not region-specific as studies from Europe to 
North America have shown that 60 to 80% of the CoNS species retrieved from 
bloodstream infections were resistant to methicillin (MR-CoNS) [231–234]. Not surpris-
ingly, such isolates often present increased tolerance to most β-lactam antibiotics, whose 
structure and mechanism of action are similar to methicillin [235,236]. The resistance to 
the action of β-lactamase was first described as the result of the hydrolysis of the β-lactam 
ring of such antibiotics, by penicillinases [237], as determined by the plasmid-mediated 
staphylococcal β-lactamase bla-Z [238]. Now, it is known that staphylococcal species can 
produce a specific penicillin-binding protein (PBP2a), which is responsible to completely 
inactivate the activity of most β-lactams, and that this resistant phenotype is complex and 
related to the existence of SCCmec, a staphylococcal cassette chromosome containing the 
mecA gene, which encodes the PBP2a protein [239–241]. Importantly, already back in the 
1980s, it was found that only about 10–20% of CoNS isolated from nosocomial infections 
were penicillin-susceptible, contrary to the 80% of commensal isolates being susceptible 
to methicillin [242,243]. Thisseems to remain true in the present days, where more than 
90% of CoNS isolated in the hospital settings present increased resistance to penicillin-
derived antibiotics [222,229,244]. 
4.2. Resistance to Other Antibiotics 
Over the years, there has been an increase in the number of CoNS strains resistant to 
glycopeptides, which are the antibiotics often used to treat MR-CoNS infections, as well 
as the emergence of resistance to newer antibiotics, hindering the current treatment op-
tions. For instance, S. epidermidis was shown to be resistant to up to eight distinct antibi-
otics with different mechanisms of action and it is estimated that, among nosocomial iso-
lated strains, 80% of the isolates present resistance to antibiotics beyond methicillin 
[232,245]. Contrasting with previous studies with a broad range of CoNS, where few iso-
lates and species presented increased tolerance to antibiotics like vancomycin and 
teicoplanin [246–248], the emergence of isolates with reduced susceptibility to glycopep-
tides has been reported in several species (Table 1). Surprisingly, resistant isolates of S. 
epidermidis [249,250] and S. haemolyticus [251,252] were detected already three decades 
ago. S. warneri [253–255] and S. capitis [256,257] have also joined the list with several iso-
lates resistant to vancomycin, generating outbreaks especially in neonatal units, where S. 
epidermidis resistant isolates are also frequently found [258]. Fortunately, vancomycin re-
mains an effective antibiotic against most of the CoNS isolates [189,222,245,259], being on 
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the top list of antibiotics used to fight these infections, either alone or in combination with 
other antibiotics as cefazolin [209], rifampicin [213,260], and fosfomycin [261], among oth-
ers. Rifampicin is also frequently used to treat staphylococcal infections; however, this 
antibiotic is associated with the rapid development of resistance when used alone and, as 
such, it should be used as part of a combined therapy [262–264]. For instance, the use of 
vancomycin or levofloxacin with rifampicin has been proved to be a good combination to 
treat these infections [213]. Significant and concerning increases in the resistance to ciprof-
loxacin, clindamycin, erythromycin, gentamicin, and tetracycline have been found over 
the last few years [22,191,219,265–270]. Resistance to tetracycline is commonly based on 
the acquisition of mobile resistance genes that lead to the dissociation of tetracyclines from 
their ribosomal binding sites and transportation of the antimicrobial agents out of the cell 
through drug efflux pumps [271,272]. Linezolid belongs to a newer class of antibiotics 
(oxazolidinones) and appeared as a promising alternative to fight staphylococcal infec-
tions with multi-drug resistance to common antibiotics [273,274], including glycopep-
tides, to which bacteria have already developed resistance mechanisms. Nevertheless, re-
sistance to linezolid has already been reported in staphylococci including CoNS [275,276]. 
Another antimicrobial belonging to the next-generation antibiotics is daptomycin, which 
has proven to be more effective than vancomycin against MR-CoNS [277]. Despite being 
a new antibiotic, there are already reports of isolates resistant to daptomycin [278], hence, 
the combination therapy with other antibiotics as rifampicin [279] may be suggested. 
Table 1. Reports of antimicrobial resistance of the 20 more frequently isolated CoNS against the 20 main antibiotics used 
in clinical and veterinary settings. 
   











































Ampicillin +[280] +[281] +[282] +[280] +[283] +[284] +[280] +[284] +[280] +[283] 
Cefazolin +[280] +[280] NF 2 +[280] NF 2 +[191] +[280] +[280] +[280] +[285] 
Fosfomycin +[257] +[286] NF 2 +[287] +[288] +[289] NF 2 +[290] +[287] +[287] 
Imipenem +[280] +[291] NF 2 +[280] NF 2 +[291] NF 2 +[280] +[280] NF 2 
Methicillin +[256] +[281] +[292] +[293] NF 2 +[294] +[293] +[294] +[294] +[294] 
Penicillin +[295] +[296] +[297] +[284] +[283] +[284] +[298] +[284] +[299] +[300] 
Oxacillin +[301] +[296] +[282] +[296] NF 2 +[284] +[302] +[299] +[299] +[300] 
Teicoplanin  +[303] +[304] NF 2 +[305] NF 2 +[298] +[302] +[290] +[302] +[306] 



















Ciprofloxacin  +[310] +[296] +[297] +[296] NF 2 +[310] +[302] +[310] +[300] +[300] 
Levofloxacin   +[301] NF 2 +[311] +[191] NF 2 +[300] NF 2 +[301] +[301] +[300] 



















Clindamycin +[301] +[286] +[311] +[284] NF 2 +[284] +[302] +[284] +[301] +[300] 
Erythromycin +[301] +[296] +[297] +[284] +[313] +[299] +[284] +[299] +[299] +[314] 
Gentamicin +[301] +[296] +[297] +[296] NF 2 +[310] +[315] +[299] +[299] +[300] 
Linezolid +[295] NF 2 +[316] +[317] NF 2 +[318] +[302] +[300] +[300] +[300] 
Quinupristin- 
Dalfopristin 
+[319] +[311] NF 2 +[284] NF 2 +[284] NF 2 +[284] +[320] +[321] 
Tetracycline +[284] +[322] +[297] +[284] +[283] +[284] +[284] +[299] +[299] +[300] 














Daptomycin + [301] NF 2 NF 2 +[311] NF 2 +[303] NF 2 +[324] +[324] +[283] 











































Ampicillin +[280] +[218] NF 2 +[280] +[280] +[315] +[280] +[282] +[284] +[284] 
Cefazolin +[280] NF 2 NF 2 +[280] +[280] NF 2 +[280] NF 2 +[280] +[280] 
Fosfomycin +[325] NF 2 +[326] +[327] +[220] NF 2 NF 2 NF 2 +[289] +[306] 
Imipenem NF 2 NF 2 NF 2 NF 2 NF 2 NF 2 NF 2 NF 2 +[328] NF 2 
Methicillin +[293] +[329] +[330] +[294] +[293] +[331] +[294] +[332] +[294] +[293] 
Penicillin +[295] +[284] +[330] +[284] +[284] +[296] +[295] +[333] +[284] +[284] 
Oxacillin +[296] +[299] +[330] +[300] +[300] +[299] +[295] +[282] +[299] +[299] 
Teicoplanin +[334] NF 2 NF 2 +[305] +[319] NF +[319] NF 2 +[304] +[335] 

















 Ciprofloxacin +[296] NF 2 NF 2 +[300] +[300] +[296] +[295] NF 2 +[300] +[310] 
Levofloxacin +[334] NF 2 NF 2 +[300] +[300] NF 2 +[320] NF 2 +[300] +[311] 



















Clindamycin +[295] +[270] +[330] +[300] +[284] +[333] +[295] +[270] +[284] +[284] 
Erythromycin +[296] +[299] +[312] +[300] +[300] +[299] +[284] +[270] +[299] +[299] 
Gentamicin +[296] +[299] NF 2 +[300] +[191] +[299] +[295] +[316] +[299] +[299] 
Linezolid +[339] NF 2 NF 2 +[330] +[300] +[340] +[295] NF 2 +[295] +[300] 
Quinupristin- 
dalfopristin 
NF 2 NF 2 NF 2 +[319] +[284] NF 2 +[284] NF 2 +[320] +[311] 
Tetracycline +[334] +[299] +[282] +[284] +[333] +[299] +[284] +[314] +[299] +[299] 














Daptomycin NF 2 NF 2 NF 2 +[283] +[284] NF 2 NF 2 NF 2 +[301] +[283] 
1 NA, nucleic acids; 2 NF—Not found. 
4.3. Antimicrobial Resistance in the Community 
Despite most of the studies being focused on clinical strains, it is known that staphy-
lococci isolated from healthy individuals may also present increased antimicrobial toler-
ance. In fact, several studies report the carriage of distinct CoNS antibiotic-resistant com-
mensal strains by the community [195,341,342], even in remote populations [227]. Alt-
hough community strains may present lower resistance rates, as, for instance, only up to 
20% of S. epidermidis commensal strains were found to be resistant to methicillin [343,344], 
contrasting with approximately 80% of resistance found among clinical isolates 
[245,345,346], the main existence of commensal strains with antimicrobial resistance colo-
nizing humans and other mammals is alarming [347]. This is especially concerning in im-
munocompromised individuals, as CoNS are often considered opportunistic pathogens 
that may cause severe infections, whose treatment would be hindered by the existence of 
isolates with antimicrobial resistance, as reviewed by Heilmann et al. [8]. The presence of 
CoNS with increased tolerance or resistance to antibiotics in animals and food is also wor-
rying. Several studies report the isolation of CoNS with multidrug resistance recovered 
from bovine mastitis [14,348], retailing chicken meat [349], livestock, bulk tank milk, and 
minced meat [25], as well as from ready-to-eat foods [23]. Undoubtedly, the presence of 
antimicrobial-resistant strains in animals represents a challenge to the animal hosts, as 
infections become harder to treat, but may also be problematic to human hosts upon trans-
mission of resistant strains resulting from close contacts between people and companion 
or farm animals [208,220,221]. 
5. Mobile Genetic Elements 
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As mentioned before, CoNS infections are associated with the establishment of bio-
films. It is actually in these complex structures that HGT phenomena are favored due to 
high cell density, high genetic competence, and availability of mobile genetic elements 
[350]. HGT is a highly important force driving bacterial evolution. Bacterial adaptation to 
new niches and environments frequently occurs through the acquisition of new genes by 
HGT processes. There are three different mechanisms to which HGT can occur: (i) trans-
formation, (ii) transduction, and (iii) conjugation. Transformation occurs when a DNA 
fragment from a dead or compromised cell enters a competent bacterial cell. Transduction 
consists of the transfer of DNA between bacterial cells through a phage. Although some 
lytic phages can transduce, generally temperate phages are more frequently associated 
with this HGT mechanism. Under the lysogenic cycle, the viral genome is integrated into 
the bacterial chromosome establishing a prophage. Under certain stimuli, phage genomes 
are excised from the bacterial genome, and, occasionally, they exchange a small piece of 
bacterial DNA for a piece of the phage genome. The newly formed phages are then com-
posed of these DNA regions that can be further inserted in new bacterial cells upon a new 
cycle of infection. Conjugation is the transfer of DNA directly from one cell to another 
through cell–cell contact. This process usually involves the transfer of plasmids. High ge-
netic relatedness has shown to be a key factor influencing HGT because, as phylogenetic 
distance increases, HGT phenomena diminish [351]. As phage propagation depends on 
host genetic similarity, transduction usually just occurs throughout the same species or 
genus [352]. In opposition, plasmids and integrative and conjugative elements can cross 
the interspecies barrier [353]. 
The HGT mechanism also influences the size of the nucleotide sequence that is trans-
ferred. While on phage-mediated transduction up to 45 kb chromosomal DNA or plas-
mids (small- or middle-sized) are transferred, larger plasmids are transferred through 
conjugation [354,355]. Moreover, in 2016, Haaber et al. discovered a mechanism named 
autotransduction in which phages are spontaneously released from the bacterial chromo-
some, and, after infecting a susceptible cell, they transfer DNA from this cell to the lyso-
genic population [356]. 
In the last decade, it was evidenced that CoNS might act as reservoirs of genes that 
can be transferred between different staphylococci, having the potential to increase the 
virulence of several species, namely S. aureus [357,358]. Indeed, genes conferring re-
sistance to all classes of antibiotics observed in CoNS are usually located on mobile genetic 
elements [359]. Staphylococcal plasmids have been shown to confer resistance to numer-
ous antibiotics, namely tetracyclines, macrolides, amphenicols, and aminoglycosides 
[360]. Different strains containing these plasmids have been isolated from different envi-
ronments, namely hospitals, veterinary, and effluents [361–363]. Despite being described 
as highly variable, the same staphylococcal plasmids have been shown to be widely geo-
graphically distributed [354]. This high similarity of plasmids, structure, and gene content 
suggests that they are transferred horizontally between strains in different environments 
[359]. 
Other key conjugative elements in staphylococci are the integrative conjugative ele-
ments (ICEs), from which two main families have been recognized both in CoPS and 
CoNS [22,355]. The transposon Tn916 and the integrative conjugative element ICE6013 
[364]. Tn916 includes the well-studied Tn5801 subfamily that encodes tetracycline re-
sistance and a protein that can inhibit restriction barriers of incoming DNA (when heter-
ologously expressed in Escherichia coli) [365,366]. ICE6013 was first discovered in S. aureus 
and described to have 15 ORFs, the shortest being known as the ICE [355]. So far, seven 
subfamilies of ICE6013 were identified with an Average Nucleotide Identity (ANI) of 68–
79% between them [364]. This element uses, as recombinase, an IS30-like transposase that 
offers versatility on the integration sites. 
Usually, in bacterial genomes, there are specific regions that are flanked by direct 
repeats, named genomic islands (GI), that are usually acquired through HGT events. On 
a sensu lato, the GI concept encompasses all elements with mobility functions, namely 
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ICEs, integrative mobilizable elements (require helper functions to conjugate), and trans-
ducible elements (SCC elements and pathogenicity islands) [367]. These GI can vary in 
size and are classified based on the products their genes encode. An important example 
is the SCCmec. This element carries the mecA gene, which is responsible for the resistance 
to methicillin and other functional genes, namely the cassette chromosome recombinase 
(ccr) genes that encode recombinases responsible for mediating the integration and exci-
sion of this element into and from the bacterial chromosome. Furthermore, SCCmec com-
prises transposons, insertion sequences, and plasmids [368]. The presence of this element 
is of great importance as it provides resistance to all penicillin-like antibiotics. Currently, 
in staphylococci, 11 different SCCmec types were described (I–XI). It is important to high-
light that, while some SCCmec types only encode resistance to β-lactam antibiotics, others 
can confer resistance to several antibiotics, as they contain transposons or integrated plas-
mids [369]. There is clear evidence that S. epidermidis can act as a reservoir of SCCmec, 
suggesting HGT events between CoNS and S. aureus [370]. 
Phage-mediated transduction events also occur on the pathogenicity islands dissem-
ination. In S. aureus, they are known as SaPIs—Staphylococcus aureus Pathogenicity Islands. 
The movement of pathogenicity islands occurs through the use of helper phage capsids. 
Usually, SaPIs encode phage-like proteins that facilitate the transfer process, such as a 
repressor (Stl) that controls SaPI excision and interaction with the helper phage. It is im-
portant to highlight that these interactions depend on the phage and the SaPI [371]. Alt-
hough SaPIs typically encode one or more virulence determinants, they are rarely com-
posed of antibiotic resistance genes. Nevertheless, SaPIs are composed of large variable 
regions that can be acquired, modified, or even removed. Despite these regions being 
widely studied in S. aureus, some orthologous regions were already identified in CoNS. 
Pathogenicity islands were already found on the S. epidermidis FRI909 strain. Although 
initially this strain was referred to as an S. aureus strain, it was further reclassified as S. 
epidermidis [372]. This SePI (Staphylococcus epidermidis pathogenicity island) is composed 
of two regions separated by repeat motifs and encodes the staphylococcal enterotoxins sec 
and sel [373]. 
Recently, Banaszkiewicz et al. analyzed more than 1500 staphylococci genomes and 
found out that five S. epidermidis strains contained the same number of ORFs (n = 29) as S. 
epidermidis FRI909 [374]. Moreover, several other strains were only missing a small num-
ber of these ORFs. The authors concluded that these SePI-associated elements present in 
S. epidermidis can be related to the acquisition of virulence-associated genes, suggesting 
that gene exchange between S. aureus and CoNS can lead to the emergence of new highly 
pathogenic S. epidermidis strains [374]. 
As stated before, phages are involved in HGT by being responsible for transduction 
events. The majority of bacterial species contain prophages in their genomes, being re-
sponsible for an important genetic variability [375]. Throughout their genomes, pro-
phages encode a set of genes that can contribute to bacterial virulence or fitness [376]. For 
the referred reasons, phages play an essential role in bacterial evolution and adaptation. 
Regarding staphylococci prophages, the vast majority of the studies are performed with 
S. aureus [377–380]. Several phage-encoded virulence factors have been described for this 
pathogen, for example, Panton–Valentine leukocidin, exfoliative toxin A, enterotoxin S, 
staphylokinase, and the staphylococcal complement inhibitor [379]. Moreover, it has also 
been described that, through negative lysogenic conversion, phage integration can disrupt 
the expression of host-encoded virulence genes [381]. Despite the number of prophages 
observed in CoNS genomes being lower than in S. aureus, it has been suggested that 
phages might also be involved in the pathogenesis and evolution of CoNS [382]. The ma-
jority of the staphylococcal prophages belong to the Siphoviridae family. Prophages were 
already described on several species, namely S. epidermidis, S. carnosus, S. hominis, S. capi-
tis, and S. haemolyticus [383–387]. Regarding genomic structure, CoNS and S. aureus pro-
phages are very similar. An important difference between them is that the majority of the 
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virulence factors observed in S. aureus are absent in CoNS prophages. The close relation-
ship observed between staphylococci prophages may increase the probability of pro-
phage-mediated HGT between different staphylococcal species [384]. Generally, it has 
been speculated that mobile elements have transferred from CoNS to S. aureus [358]. Clus-
tered Regularly Interspaced Short Palindromic Repeats (CRISPR) elements found in CoNS 
isolates determine incorporation of foreign DNA into the genome and may limit the ac-
quisition of mobile genetic elements, including enterotoxin genes [34]. Consequently, we 
might expect the unidirectional acquisition of mobile elements from CoNS by S. aureus. 
This evolutionary scenario explains the acquisition of the SCCmec cassette, Arginine cat-
abolic mobile element (ACME), and sasX genes from CoNS [388,389]. However, the dis-
tribution of CRISPR elements is much lower in S. epidermidis and other staphylococci than 
previously thought and there is recent evidence of frequent HGT and exchange of mobile 
genetic elements within and between staphylococcal species [390,391]. S. aureus may even 
act as a source of mobile elements for CoNS, including pathogenicity island exchange, as 
demonstrated by the transduction of S. aureus SaPI to S. xylosus and S. epidermidis 
[392,393]. 
6. Bacteriocins 
Due to the highly competitive and polymicrobial environment that bacteria live in, 
they have developed several defense mechanisms for self-preservation. These mecha-
nisms include, among others, the production of molecules with quorum quenching ability 
[394,395], exotoxins [396,397], antibiotics [398], and bacteriocins [399,400]. 
Bacteriocins, defined as ribosomally synthesized peptides with antibacterial proper-
ties [401], are one of the most widely distributed microbial defense mechanisms. Indeed, 
it is estimated that 99% of bacteria produce at least one bacteriocin [402]. These molecules 
allow the producer to outcompete the competitors in its surroundings, to invade new and 
established niches and, ultimately, can modulate the composition of the involving micro-
biota [403,404]. Both Gram-positive or -negative bacteria have the capacity to produce 
bacteriocins, but the vast majority reported so far are produced by the former [405,406]. 
Due to the great diversity of bacteriocins produced, their classification has been a motive 
of controversy, having classes/subclasses been proposed and withdrawn over the years. 
One of the most comprehensive and straightforward classification systems categorizes the 
bacteriocins produced by Gram-positive bacteria into four classes [407]. Class I bacterioc-
ins comprise small peptides (<5 KDa) that go through extensive post-transcriptional mod-
ifications containing, thus, unusual amino acids in its composition. Class II also compre-
hends small peptides (<5–10 KDa) but without or with minor post-transcriptional modifi-
cations. Class III includes large proteins (>10 KDa) and class IV comprehends complex 
bacteriocins that are conjugated with lipids or carbohydrates moieties [407]. More detailed 
information about the structure, characteristics, properties, and modes of actions of each 
class of bacteriocins produced by Gram-positive bacteria, in particular produced by 
CoNS, are comprehensively and recently reviewed elsewhere [408,409]. Although initially 
thought to only target closely related bacteria, some bacteriocins have a broader spectrum 
of activity affecting bacteria across different genera [410] or even transphylum [407]. Be-
sides presenting a variable spectrum of activity, their high diversity [411], high stability 
at elevated temperatures and wide range of pH [412,413], relatively low cytotoxicity 
[407,414], and amenability to bioengineering [410] render bacteriocins interesting for an 
array of applications in food, agriculture, veterinary, cosmetics, and pharmaceutical in-
dustries (reviewed in [415–417]). 
Considering that the production of bacteriocins is triggered by the surrounding com-
petitors, CoNS being found in a variety of environments and hosts [418] they produce 
bacteriocins with far-reaching activity targeting pathogens that affect foodstuff, plants, 
animals, and humans (reviewed in [409]). The majority of the bacteriocins produced by 
CoNS are lantibiotics [400], which are characterized by harboring the unusual and non-
proteinogenic amino acids lanthionine and 3-methyllanthionine [419]. S. epidermidis is 
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known to produce several lantibiotics such as Pep5 [420], epidermin [419], epicidin 280 
[421], epilancin k7 [422], epilancin 15× [423], and nukacin IVK45 [424]. Likewise, other 
CoNS produce other important lantibiotics such as gallidermin (S. gallinarium) [425], hom-
inicin [426] and nukacin KQU-131 [427] (S. hominis), nukacin ISK-1 [428] and SWLP1 [429] 
(S. warneri), nukacin 3299 [430] (S. simulans), and Nisin J [431] (S. capitis). However, CoNS 
also produce bacteriocins belonging to other classes such as the epidermicin NI01 (pro-
duced by S. epidermidis) [432] and capidermicin (S. capitis) [433], which belong to class II, 
and endopeptidade ALE-1 (S. capitis) and lysostaphin (S. simulans) [434] that belong to 
class III bacteriocins. Because (i) several staphylococcins target clinically important path-
ogens such as S. aureus, including methicillin-resistant and vancomycin-intermediate, (ii) 
the shortage in novel and efficient antibiotics, (iii) the increase in antibiotic resistance, and 
(iv) the lower toxic effect of bacteriocins when compared to antibiotics [406], the potential 
use of staphylococcins against both human and animal pathogens has been particularly 
explored (reviewed in [408,409]). Despite the promising results obtained in vitro, both in 
planktonic and biofilm modes of growth [426,431,433–436], only a few staphylococcins, 
namely lysostaphin [437–439] and epidermicin NI01 [440,441], were evaluated using in 
vivo models. These two bacteriocins constitute promising candidates as therapeutic anti-
microbial agents, lysostaphin currently being in late clinical trials for topical application 
[409]. 
As a result of their natural origin and consumers demands for products with no 
chemical additives, the interest for bacteriocins in food preservation has increased. Several 
bacteriocins, mainly produced by lactic acid bacteria, have been used in food industries 
for many years already [442,443] being Nisin, planctaracin, sakin P, and pediocin the most 
commonly used and commercially available [442]. While not as explored, the application 
of the staphylococcins in food processing environment is encouraging since, as mentioned 
before, several bacteriocins produced by CoNS target S. aureus strains, which are one of 
the most important causative agents of food poisoning [444]. Indeed, recently, it was re-
ported that pep5 and lysostaphin showed a remarkable capacity to reduce (between 95% 
and 99.99%) the load of enterotoxigenic S. aureus strains in cheese samples [445]. 
Despite its advantages and efficacy, substantial use of bacteriocins in the large scale 
industry was not yet conquered. This is mainly due to the difficulty to obtain practical 
quantities of its pure form and due to the high costs associated with its production and 
purification. While for food application partially purified and even crude preparations 
may be used, for clinical applications, pure bacteriocins are necessary [409]. As such, the 
biotechnological application of bacteriocins, as well as staphylococcins, has been delayed. 
However, since bacteriocins constitute excellent candidates to substitute antibiotics, the 
scientific community has not given up on bacteriocins just yet. As a result, to improve 
bacteriocins usage, research has shifted to a new paradigm, bacteriocins molecular engi-
neering, to create variants of natural bacteriocins with improved solubility, stability, effi-
cacy, pharmacokinetics, and to overcome the production and purification issues [403,446–
448]. 
7. Impact on Health 
The vast majority of infections caused by CoNS only rarely develop into life-threat-
ening diseases. However, due to the variety of infections, their high frequency, and be-
cause they are extremely difficult to diagnose and treat, the infections caused by CoNS 
represent a serious burden for the public health system and, more importantly, have seri-
ous consequences on patients’ quality of life. The major risk factor for the development of 
infections with CoNS is the presence of IMD. These are essential for monitoring the pa-
tient’s vital functions, diagnosis, delivery of nutrients and/or drugs, and to support or 
replace failing organs [449]. As such, every year, millions of devices are used in industri-
alized countries [450–452]. However, while essential, IMD also provide a way into the 
human body and serve as a scaffold for biofilm formation by CoNS, these being capable 
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of forming biofilms on a plethora of IMD (reviewed in [8,418,450,453] ). Furthermore, pa-
tients’ clinical conditions is another important risk factor, the most prone to develop in-
fections caused by CoNS being the ones with immature or fragile immune systems such 
as preterm new-borns, elderly patients, patients with leukopenia, neutropenia, going 
through immunosuppression treatments, transplantation, chemotherapy, and care in in-
tensive and burn care units [8,450]. With an increasing number of vulnerable patients, it 
is predicted that the number of people who can benefit from implantable devices will 
continue to rise. As a result, CoNS infections associated with the use of IMD will tend to 
rise, putting millions of patients at risk and an enormous economic pressure on healthcare 
systems. 
7.1. Infections Caused by CoNS 
CoNS are a very heterogeneous group having only a few species been regularly im-
plicated in human infections (reviewed in [8,418]). In addition, there are differences re-
garding CoNS pathogenicity, having species that are considered completely innocuous, 
such as S. carnosus, other that display a medium-pathogenic profile as S. epidermidis and 
S. haemolyticus and, finally, others that are considered more virulent such as S. lugdunensis 
[27]. 
With regard to IMD-related infections, S. epidermidis is by far the most representative 
species of the group, followed by S. haemolyticus, S. hominis, and S. saprophyticus [8]. Blood-
stream infections (BSI) are the most common outcome of CoNS colonization of medical 
devices and are especially associated with the use of intravascular catheters or implant 
ports [454,455]. Moreover, BSI can also arise from the colonization of other types of de-
vices, for example, prosthetic heart valves [456], cardiac assist devices [457,458], and cor-
onary stents [459]. Of note, BSI caused by CoNS independently of the use of medical de-
vices can also occur, mainly affecting preterm newborns [460] and neutropenic patients 
[461]. BSI symptoms can be subtle and nonspecific at the beginning but may lead to severe 
complications and a fatal outcome being, thus, a major concern within the infections 
caused by CoNS infections [8,418,462]. 
In addition to BSI, CoNS can also cause local infections when colonizing medical de-
vices without access to the bloodstream. Drain-associated cases of meningitis/ventriculits 
[463], endophtalmitis [464,465], peritonitis [466] and cerebrospinal fluid shunt- [467], pros-
thetic joint- [468,469], mammary implants-[470,471], and surgical sites-associated infec-
tions [455,472] are some examples. 
While more representative, CoNS are not only linked with the development of infec-
tions related to the use of IMD. Cases such as healthcare-associated native valve endocar-
ditis in adults [473], meningitis [474], and necrotizing fasciitis [475] in preterm infants 
were also reported. Moreover, confirming CoNS versatility, several CoNS species have 
been also implicated in laryngological diseases (rhinosinusitis, sinusitis) and infections 
(frontal sinus, throat, larynx, nares, tonsils, and trachea infections) (reviewed in [476]). 
7.2. Evasion from the Host Immune System 
Amongst the strategies used by CoNS to protect themselves from the host immune 
system, biofilm formation is one of the most important [477]. This is partially related to 
the fact that biofilms are composed of molecules with important protective roles and be-
cause it harbors cells with a wide range of metabolic activities. 
Regarding biofilm-associated molecules, PNAG, the major component of S. epider-
midis biofilms, has a significant function in bacterial cell protection. PNAG was found to 
protect S. epidermidis biofilm cells from several host defense mechanisms such as neutro-
phils and macrophage killing, complement deposition, immunoglobulins, and antimicro-
bial peptides action (AMPs) [33,478–480]. It is noteworthy that PNAG deacetylation was 
shown to be crucial for immune evasion [481–484]. The mechanism by which PNAG pro-
tects cells from AMPs is often related to electrostatic repulsion (positive/positive charge). 
Interestingly, PNAG also protects against negatively charged AMPs, namely dermicin, 
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suggesting that PNAG functions as a decoy by sequestrating oppositely charged AMPs 
[479]. Additionally, S. epidermidis has an AMP-sensing system that activates mechanisms 
that decrease the overall negative charge of the bacterial cell wall, thereby hindering the 
efficient attraction of cationic AMPs [485]. These include the D-alanylation of TAs [61], as 
described earlier, and the lysylation of membrane phospholipids by the MprF (also known 
as FmtC) [486]. The production of the extracellular enzyme SepA has an important func-
tion in the protection against AMPs, as it promotes AMPs’ proteolytic breakdown. Fur-
thermore, it was reported that SepA confers protection of S. epidermidis cells against being 
killed by neutrophils [487]. There are, yet, other findings showing the pro-inflammatory 
effect of PNAG [478,488,489]. On the one hand, these apparently contradictory results may 
be related to the distinct models used in the different studies performed and due to the 
difficulty to attribute the observed effects directly to PNAG molecule as (i) it is challenging 
to obtain PNAG molecule in high purity and (ii) because PNAG-deficient strains have 
distinct cell surface properties, which together may influence the host response [490]. On 
the other hand, these results show the complex balance of the immune response elicited 
by S. epidermidis. 
In addition to PNAG, S. epidermidis produces another exopolymer, the poly-γ-glu-
tamic acid, whose production was found to be upregulated in the biofilm phenotype [491], 
and that has also been implicated in the defense against the host immune system attack. 
Although its primary function is to allow S. epidermidis to survive in high salt concentra-
tions environments, like the human skin, it seems important to resist phagocytosis by neu-
trophils and AMP action [492]. Of note, the proteins Aap and Embp are involved as well 
in the protection of S. epidermidis biofilm cells as both seem to hamper macrophage phag-
ocytosis [74,493]. 
PSMs also have a part in the protection of S. epidermidis cells against the investiture 
of the effectors of the host immune system. Among the PSMs produced, some present 
potent cytolytic activity against human neutrophils such as the PSMε and PSMδ [487,494]. 
Interestingly, although S. epidermidis has the potential to produce effective cytotoxins, 
these are produced in lower quantities [487]. These findings indicate that S. epidermidis 
prefers to employ a rather passive strategy to stimulate a low inflammatory profile and, 
this way, achieve a successful evasion from the host immune system [487]. 
Lastly, in regard to the metabolic heterogeneity of S. epidermidis biofilm cells and the 
advantage in the evasion from the host immune system, the presence of VBNC cells is an 
important factor (for more details, see Section 2). Earlier, it was demonstrated that S. epi-
dermidis biofilms with higher proportions of VBNC are less inflammatory inducing, thus, 
less phagocytosis by murine macrophages, both in vitro and in vivo [172]. 
7.3. Diagnostics 
As part of human flora, the diagnostic of the infections caused by CoNS is often con-
fusing, as their presence in clinical samples does not unequivocally indicate infection, pos-
sibly being the result of contamination during sample collection [495]. Hence, it is puz-
zling to assess the clinical relevance of a positive culture frequently resulting in (i) signif-
icantly longer hospital stays, extra diagnostics, and treatments, (ii) application of unnec-
essary treatments that greatly contribute to the antibiotic selection pressure and, finally, 
(iii) delayed application of the adequate treatment regimen that ultimately can lead to 
patient mortality [8]. Consequently, to alleviate such issues, over the years, several studies 
have been performed in the direction of finding markers with the capacity to distinguish 
between S. epidermidis that live on the skin from those that cause infections. However, 
since the CoNS virulence factors are the same that confer its fitness as a commensal (re-
viewed in [42]), this task is rather challenging. 
Based on several studies, it was observed that commensal strains seem to be more 
susceptible to antibiotics [496], often positive to the genes aap and fdh and the ACME ele-
ment [154,496–498] and repeatedly negative to the biofilm-associated genes icaA and bhp 
and the IS256 [499,500]. In the case of clinical isolates, it has been often linked to higher 
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antibiotic resistance and the presence of the genes icaA and bhp, as well as the carriage of 
the IS256 and SCCmec elements [496–498,501–503]. In addition, a phylogenetic analysis of 
S. epidermidis isolates from healthy human skin infections showed the presence of two 
separate clusters, the lineage A/C and B [154,504]. The strains belonging to the first lineage 
contained most of the isolates from colonization and infection, while the lineage B was 
mainly composed of colonization isolates [154,504]. Recently, the genotypic and pheno-
typic differences between both lineages were characterized supporting the higher patho-
genic potential of the strains belonging to the A/C lineage and the potential of fdh to be 
used as a marker for commensal isolates [505]. 
Even so, a novel diagnostic strategy based on these putative markers is not yet under 
use or, as far as we know, under consideration. As such, more studies are necessary. So 
far, the majority of the studies have relied on DNA or phenotype analysis; however, con-
sidering that gene transcription is altered depending on the conditions of the involving 
environment, the analysis on how commensal and clinical isolates respond in the course 
of infection by analyzing its transcriptome may hold the key to find suitable markers. 
7.4. Alternative Treatment Strategies 
Aside from the difficulty associated with the accurate diagnosis of CoNS infections, 
the increasing resistance of CoNS to multiple antibiotics agents together with the high 
tolerance to antibiotics demonstrated when growing in biofilms [31], are critically reduc-
ing the treatment options since antibiotics remain the primary form of treatment. Thus, a 
serious effort has to be made to manage the plethora of infections caused by CoNS as these 
primarily affect a growing and susceptible population of our society. As such, in the last 
few decades, researchers have been tackling this issue from different angles. 
7.4.1. Immunoprophylaxis and Immunotherapy Strategies 
Considering that the majority of the infections caused by CoNS are associated with 
biofilm formation on IMD, surface and matrix molecules involved in this process were 
initially addressed [506–508]). PNAG was one of the first molecules to be targeted due to 
its role in immune evasion and also because it is the principal mediator of biofilm for-
mation in staphylococcal species. In S. epidermidis, it was shown that human monoclonal 
antibodies (mAbs) against PNAG were effective in killing planktonic and biofilm cells in 
opsonophagocytic in vitro assays [33]. In addition, it was shown that mAbs anti-PNAG 
inhibited biofilm accumulation in vitro and were protective in a rabbit endocarditis model 
[509]. However, biofilm accumulation inhibition in the presence of mAb anti-PNAG 
seems to be strain-dependent [510]. The potential of several proteins such as Aap, SesC, 
and SdrG as target candidates for antibody-based therapies was also considered. Biofilm 
formation by S. epidermidis was impaired by mAbs anti-Aap, but in a biomaterial-associ-
ated infection model, neither enhanced opsonophagocytosis nor protected mice were ob-
served [511,512]. On the other hand, polyclonal rabbit sera against SesC were shown to 
significantly inhibit S. epidermidis biofilm formation in vitro and in vivo and vaccination 
with recombinant SesC reduced S. epidermidis biofilm formation and infection rate in an 
animal model [73,103]. The incubation of S. epidermidis with antibodies anti-SdrG previous 
to challenge reduced the bacterial load in the kidneys of infected mice [513]. Later on, it 
was shown that previous vaccination of mice with antibodies anti-SdrG conferred protec-
tion [514]. Due to their relevant role in biofilm formation and maintenance, TAs [515,516] 
and β-type PSM [114] were also explored. Nevertheless, despite encouraging results, anti-
staphylococcal vaccines or immunotherapy strategies have failed clinical trials [517–519]. 
By analyzing all failed attempts, it became clear that targeting a single antigen has limited 
success and, thus, a multivalent approach would increase the chances of developing ef-
fective vaccines. Hence, new advances were made in the past few years, reviving the in-
terest in developing vaccines against infections caused by staphylococcal species 
[507,520]. 
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7.4.2. Interfering Molecules 
To prevent or eradicate staphylococcal biofilms, a vast range of substances with dif-
ferent mechanisms have been identified (reviewed in [129,521]. As mentioned before, dis-
persin B degrades PNAG, leading to biofilm dispersion [119]. In addition, DNases and 
proteases, which may be self-produced, can be used to interfere with the stability of 
eDNA- and protein-based biofilms, respectively. Nevertheless, the application of dispers-
ing agents has limitations as it leads to the spreading of bacterial cells and may also result 
in an aggressive response of the host immune system [127]. As such, it was established 
that dispersion agents need to be applied together with antibiotics to be effective. One 
shall consider that the cells released from biofilms have a particular phenotype showing, 
in S. epidermidis, higher tolerance to a few antibiotics [126]. In addition, it is important to 
consider the side effects of applying molecules with broad activity, such as proteases, as 
these may interfere with host proteins and tissues [129]. Other interesting molecules al-
ready discussed in this review are bacteriocins. Gallidermin [435] and nisin [522], for in-
stance, seem to be able to efficiently prevent S. epidermidis biofilm formation and disrupt 
established biofilms, respectively. Finally, the use of molecules with the capacity to arrest 
QS communication among cells, called quorum quenching molecules, is being revisited 
and promising results were obtained in S. aureus [523]. 
7.4.3. Phages and Phage-Derived Enzymes 
Another interesting strategy to treat biofilm-related infections is the use of phages 
and phage-derived enzymes (reviewed in [524,525]) as these present a narrow host speci-
ficity preventing, thus, the killing of beneficial bacteria during treatment. In addition, 
phages can affect antibiotic-susceptible and -resistant bacteria [526]. 
Phages can be used alone or in combination with other molecules such as antibiotics 
or dispersion agents and, to increase the efficacy of the treatment, two or more phages can 
be mixed [129]. Phage K is a well-documented polyvalent staphylococcal phage with re-
ported activity against S. epidermidis biofilm cells [527]. More recently, a S. epidermidis-
specific phage (SEP1) was shown to infect different S. epidermidis planktonic cells, namely 
on exponential and stationary phases [528]. Although not able to infect intact biofilms, 
SEP1 was able to infect scraped biofilms, persister and biofilm-released cells, suggesting 
that its activity was affected by the biofilm matrix [85]. 
Regarding phage-derived enzymes, the endolysin LysGH15 was able to eliminate 
planktonic cells, as well as to inhibit and disrupt biofilms formed by S. epidermidis, S. hae-
molyticus, and S. hominis. Moreover, the efficacy of LysGH15 was analyzed in vivo and a 
lower bacterial load was observed in the blood and solid organs when compared with the 
control [529]. Another lysin, the CF-301, has also shown to be efficient against biofilms 
formed by several CoNS species, on different surfaces, including mixed-species composed 
of S. aureus and S. epidermidis [530]. In another study, a phage-origin extracellular poly-
meric substance (EPS)-depolymerase (Dpo7) was shown to be able to prevent and dis-
perse staphylococcal biofilms in polysaccharide-dependent biofilm forming strains [531]. 
Notwithstanding, despite the efforts made, the current existing strategies to fight 
staphylococcal infections consist of antibiotics and preventing the colonization of medical 
devices before implantation by increasing hygiene and disinfection measures [477]. 
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8. Enterotoxins and Impact on Food 
While the highly virulent S. aureus is usually responsible for acute infections, CoNS 
mostly differs from S. aureus by being less virulent, being frequently associated with 
chronic infections. Generally, CoNS pathogenicity is associated with some molecular 
mechanisms that evolved for a commensal lifestyle on the skin that can have extra use 
throughout infection development [42]. In opposition to S. aureus, generally, CoNS strains 
do not produce aggressive toxins [42]. Staphylococcal enterotoxins compose a family of 
toxins that are analogous both chemically and biologically. Upon ingestion of these toxins, 
a disease called staphylococcal food poisoning (SFP) can occur. This usually happens due 
to improper handling or storage of staphylococcal contaminated foodstuff, such as meats, 
salads, creams, and dairy products. In 2012, the CDC estimated that, in the United States 
of America, SFP caused >240,000 illnesses leading to >1000 hospitalizations and six deaths 
per year [532]. This happens usually on meats, salads, creams (bakery), and dairy products 
[533]. The presence of S. aureus in food is considered a public health hazard for its ability 
to produce enterotoxin and the risk of development of consequent food poisoning. After 
ingestion of the toxin, a typical incubation period of 6–10 h is expected. Usual symptoms 
include headache, nausea, abdominal cramps, vomiting, general weakness and prostra-
tion, dizziness and chills, and diarrhea (sometimes containing blood) [534]. To date, there 
are nine different staphylococcal enterotoxins identified that are designated as A, B, C1, 
C2, C3, D, E, F, and G. However, enterotoxins A and D are responsible for the majority of 
the outbreaks [535]. These toxins are members of the pyrogenic toxins family that have 
the capability to stimulate a high percentage of T cells, thereby acting as superantigens. 
They are highly thermostable and therefore difficult to inactivate in the human body [534]. 
In a recent study with more than 1500 staphylococcal genomes analyzed, enterotoxin-en-
coding genes were detected in 97% of the S. aureus genomes (857 out of 883), while only 
nine genes were detected in S. epidermidis. Around 70% of the S. aureus genomes were 
reported to encode genes forming enterotoxin gene clusters, where the selx gene was 
found to be the most frequent (782 strains). The nine S. epidermidis strains mentioned en-
coded both sec and sel genes. In the mentioned study, a phylogenetic analysis was also 
performed, and the authors observed that all nine enterotoxigenic S. epidermidis strains 
belonged to a cluster of 65 strains very distant from the other 499 strains [374]. Despite 
these rare reports about the presence of enterotoxins in CoNS, their impact on virulence 
is still not clear [358]. CoNS strains have rarely been associated with food poisoning as 
they usually do not grow rapidly in foods. However, some enterotoxin-producing CoNS 
strains have been isolated from cases of SFP [536,537]. However, although with low fre-
quency, several studies reported that different CoNS isolated from poultry can encode 
toxin-producing genes [538,539]. CoNS species such as S. epidermidis, S. gallinarum, S. ar-
lettae, S. chromogenes, and S. xylosus have commonly been isolated from the skin and nares 
of chickens [540]. Despite being part of chicken microbiota as harmless colonizers, it is 
now accepted that some of these species can be pathogenic under specific conditions. In-
deed, commensal strains are seen as a reservoir of antibiotic-resistant genes, and that jus-
tifies why slaughter poultry has been recognized as one of the most important vehicles 
for the dissemination of antimicrobial resistance genes [21]. CoNS are stated as playing a 
major role in the development of sensory properties in fermented foods and sausages 
[541]. Particularly, S. carnosus, S. equorum, S. succinus, and S. xylosus are known to produce 
low molecular-weight compounds that have a high impact on product flavor [541]. More-
over, for safety reasons, several CoNS strains have been selected as starter cultures in meat 
fermentation processes [542]. 
As abovementioned, some CoNS, namely S. epidermidis, S. haemolyticus, and S. sapro-
phyticus, have been associated with nosocomial infections, and these species are also fre-
quently associated with foodstuff. Genomic analysis of these strains proved that CoNS are 
a reservoir of antibiotic-resistant genes. As S. aureus and S. epidermidis usually inhabit sim-
ilar ecological niches, gene flow between these two species is predicted to occur with high 
prevalence. This can ultimately lead to the emergence of S. epidermidis toxigenic strains. 
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Consequently, in the future, the possibility of SFP caused by CoNS strains should be con-
sidered. 
9. Conclusions 
As clearly shown in this review series, CoNS are a versatile group of staphylococcal 
species that are equipped with the necessary factors and strategies to withstand the host 
and/or involving environment stresses. In regard to CoNS clinical implications, consider-
ing that modern medicine mainly relies on the use of medical devices and the current shift 
in patient’s demographics towards increased numbers of vulnerable patients, it is likely 
that CoNS-caused infections will become even more frequent, contributing to overall mor-
bidity, mortality, and socioeconomic distress. When it comes to CoNS repercussion in the 
food processing environment, while the production of enterotoxins has been described in 
CoNS, these are not generally accepted as enterotoxins producers and, as such, the role of 
CoNS in foodborne diseases has been overlooked. However, because CoNS are commonly 
found in food and share the same niche with S. aureus, through HGT events, it is predicted 
that the interest in these species as foodborne pathogens will increase over the next years. 
However, much remains to be done to further comprehend the involvement of CoNS in 
the emergence of foodborne diseases. 
Overall, considering that antibiotics are still our primary form of treatment and that 
these are greatly inefficient against CoNS-caused infections, in particular against biofilm-
originated infections, there is an urgent need to find new alternatives. To overcome this 
challenge, it is necessary to endorse more basic and clinical research aiming to (i) underpin 
CoNS colonization mechanisms, reservoir function, and the dichotomy commensal/path-
ogen; (ii) elucidate the mechanisms promoting antibiotic resistance, as well as tolerance; 
(iii) characterize CoNS in-host evolution as well as the host response. In addition, further 
applied research addressing the development of alternative methods to prevent and/or 
eradicate CoNS biofilms such as (i) the development of new biomaterials and coatings to 
avoid bacteria initial attachment, (ii) the search for effective phages and phage-derived 
enzymes as well as (iii) interfering molecules need to be supported. Only this way will the 
scientific community have the means to seriously tackle this issue and, at last, develop 
effective strategies to control the infections caused by CoNS. 
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